An update of safety of clinically used atypical antipsychotics.

An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf. 2016 Jun 27; Authors: Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo A, Martinotti G, Mazza M, Perna G, Carano A, de Bartolomeis A, Di Giannantonio M, De Berardis D Abstract INTRODUCTION: The atypical antipsychotic (APs) drugs are a class of agents that have become the most widely used agents to treat a variety of psychoses because of their superiority with regard to safety and tolerability profile, particularly regarding to their lower/absent propensity to induce extrapyramidal symptoms (EPS), compared to conventional/'typical' APs. AREAS COVERED: We aimed at providing a synthesis of most current evidence about the safety and tolerability profile of the most clinically used atypical APs so far marketed. Qualitative synthesis followed an electronic search made inquiring of the following databases: MEDLINE, Embase, PsycINFO and the Cochrane Library from inception until January 2016, combining free terms and MESH headings for the topics of psychiatric disorders and all atypical APs as following: ((safety OR adverse events OR side effects) AND ((aripiprazole OR asenapine OR quetiapine OR olanzapine OR risperidone OR paliperidone OR ziprasidone OR lurasidone OR clozapine OR amisulpride OR iloperidone)). EXPERT OPINION: A critical issue in the treatment with atypi...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research